These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20304705)

  • 1. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
    Seliger B; Massa C; Rini B; Ko J; Finke J
    Trends Mol Med; 2010 Apr; 16(4):184-92. PubMed ID: 20304705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of tyrosine kinase inhibitors in tumor immunology.
    Nishioka Y; Aono Y; Sone S
    Immunotherapy; 2011 Jan; 3(1):107-16. PubMed ID: 21174561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
    Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
    Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
    Fujimura T; Mahnke K; Enk AH
    J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cells, tumour immunity and immunotherapy.
    Zou W
    Nat Rev Immunol; 2006 Apr; 6(4):295-307. PubMed ID: 16557261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCL5 as an adjuvant for cancer immunotherapy.
    Lapteva N; Huang XF
    Expert Opin Biol Ther; 2010 May; 10(5):725-33. PubMed ID: 20233026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of T lymphocytes in the immunotherapy of tumours.
    Brondz BD; Balashov KE
    Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of therapeutic approaches to gastric cancer.
    Wu K; Nie Y; Guo C; Chen Y; Ding J; Fan D
    J Gastroenterol Hepatol; 2009 Jan; 24(1):37-41. PubMed ID: 19196394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapies for melanoma.
    Katipamula R; Markovic SN
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tumours by adoptive transfer of immune cells.
    Macary PA; Too CT; Dai X
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):569-74. PubMed ID: 16700896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve immunotherapy drugs that could cure cancers.
    Cheever MA
    Immunol Rev; 2008 Apr; 222():357-68. PubMed ID: 18364014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined antiangiogenic and immune therapy of prostate cancer.
    Huang X; Raskovalova T; Lokshin A; Krasinskas A; Devlin J; Watkins S; Wolf SF; Gorelik E
    Angiogenesis; 2005; 8(1):13-23. PubMed ID: 16132614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-alpha and novel strategies of combination therapy for cancer.
    Bracci L; Proietti E; Belardelli F
    Ann N Y Acad Sci; 2007 Sep; 1112():256-68. PubMed ID: 17567945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
    van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
    Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.